Biogen, Eisai take Alzheimer’s candidate BAN2401 into phase 3
Biogen and Eisai, in collaboration with BioArctic and the Alzheimer’s Clinical Trials Consortium (ACTC), have announced the initiation of a phase 3 study of their experimental Alzheimer’s treatment BAN2401.
The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer’s disease (AD) in individuals in preclinical, asymptomatic stages of the disease. BAN2401 is an anti-amyloid beta (Aβ) protofibril antibody, designed to selectively bind to neutralise and eliminate toxic Aβ protofibrils that are thought to be one of the factors causing AD.
The AHEAD 3-45 programme includes two trials, A3 and A45, which aim to evaluated to potential of BAN2401 to reduce the accumulation of harmful amyloid beta aggregates in the brain, and also prevent cognitive decline resulting from AD.
The two trials will involve participants with different levels of amyloid beta in the brain. The A3 trial will enrol participants who have an intermediate amount of amyloid beta in the brain and who are at high-risk for further amyloid beta accumulation. The A45 trial will enrol participants with elevated levels of amyloid beta in the brain.
Read more: http://www.pmlive.com/pharma_news/biogen,_eisai_take_alzheimers_candidate_ban2401_into_phase_3_1344820
The study will evaluate the therapeutic effect of BAN2401 on the progression of Alzheimer’s disease (AD) in individuals in preclinical, asymptomatic stages of the disease. BAN2401 is an anti-amyloid beta (Aβ) protofibril antibody, designed to selectively bind to neutralise and eliminate toxic Aβ protofibrils that are thought to be one of the factors causing AD.
The AHEAD 3-45 programme includes two trials, A3 and A45, which aim to evaluated to potential of BAN2401 to reduce the accumulation of harmful amyloid beta aggregates in the brain, and also prevent cognitive decline resulting from AD.
The two trials will involve participants with different levels of amyloid beta in the brain. The A3 trial will enrol participants who have an intermediate amount of amyloid beta in the brain and who are at high-risk for further amyloid beta accumulation. The A45 trial will enrol participants with elevated levels of amyloid beta in the brain.
Read more: http://www.pmlive.com/pharma_news/biogen,_eisai_take_alzheimers_candidate_ban2401_into_phase_3_1344820
